The FDA on November 10, 2022, approved ADCETRIS® (Brentuximab vedotin) in combination with Doxorubicin, Vincristine, Etoposide, Prednisone, and Cyclophosphamide for pediatric patients 2 years of age and older with previously untreated high risk classical Hodgkin lymphoma (cHL). This is the first pediatric approval for ADCETRIS®. ADCETRIS® is a product of Seagen, Inc.
Bottom Ad
Advertisement
Subscribe
